Associations between the logical memory test story recall metrics and plasma biomarkers for Alzheimer's disease in individuals free of dementia.

IF 3 3区 心理学 Q2 CLINICAL NEUROLOGY
Ainara Jauregi-Zinkunegi, Rachael E Wilson, Rebecca E Langhough, Nicholas J Ashton, Kaj Blennow, Sterling C Johnson, Henrik Zetterberg, Davide Bruno, Kimberly D Mueller
{"title":"Associations between the logical memory test story recall metrics and plasma biomarkers for Alzheimer's disease in individuals free of dementia.","authors":"Ainara Jauregi-Zinkunegi, Rachael E Wilson, Rebecca E Langhough, Nicholas J Ashton, Kaj Blennow, Sterling C Johnson, Henrik Zetterberg, Davide Bruno, Kimberly D Mueller","doi":"10.1080/13854046.2025.2481119","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> Blood-based biomarkers are valued for their lower cost and less invasive nature, though issues with widespread implementation and accessibility remain. Process-based scores from story recall have been shown to detect neuronal network disturbances typical of Alzheimer's disease (AD) pathology more effectively than traditional metrics. This study examined the associations between process-based scores and concurrent plasma AD biomarkers in older adults without dementia, while also comparing them to traditional metrics. Additionally, it also investigated the diagnostic utility of these metrics in detecting plasma p-tau217 positivity. <b>Methods:</b> Data from 416 participants (mean age = 66.6 ± 7) free of dementia were extracted from the Wisconsin Registry for Alzheimer's Prevention (WRAP). Logical Memory Test (LMT) and plasma p-tau217, p-tau181, p-tau231, Aβ42/Aβ40 ratio, GFAP and NfL levels were analyzed. Bayesian regression models assessed associations between plasma biomarkers and both process-based and traditional LMT scores, controlling for the covariates. <b>Results:</b> The best-fitting model for plasma p-tau217 included Total ratio (Tr) and Immediate recall (BF10=573), but Tr showed stronger evidence of association (mean coefficient = 0.208; BFinclusion=14.4) than Immediate recall (mean coefficient=-0.007; BFinclusion=1.7). Tr was also the best predictor of plasma p-tau181 (mean coefficient = 0.144; BF10=10.5) and GFAP (mean coefficient = 0.141; BF10=5.8), outperforming traditional LMT scores. No memory scores were associated with plasma p-tau231 or Aβ42/40 ratio levels. Tr score was the strongest single predictor of p-tau217 positivity (BF<sub>10</sub>=38). <b>Conclusions:</b> These findings suggest that process-based memory scores might be useful in enhancing the detection of neuronal network disturbances associated with AD pathology, especially in settings where biomarker testing is unavailable.</p>","PeriodicalId":55250,"journal":{"name":"Clinical Neuropsychologist","volume":" ","pages":"1-20"},"PeriodicalIF":3.0000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neuropsychologist","FirstCategoryId":"102","ListUrlMain":"https://doi.org/10.1080/13854046.2025.2481119","RegionNum":3,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Blood-based biomarkers are valued for their lower cost and less invasive nature, though issues with widespread implementation and accessibility remain. Process-based scores from story recall have been shown to detect neuronal network disturbances typical of Alzheimer's disease (AD) pathology more effectively than traditional metrics. This study examined the associations between process-based scores and concurrent plasma AD biomarkers in older adults without dementia, while also comparing them to traditional metrics. Additionally, it also investigated the diagnostic utility of these metrics in detecting plasma p-tau217 positivity. Methods: Data from 416 participants (mean age = 66.6 ± 7) free of dementia were extracted from the Wisconsin Registry for Alzheimer's Prevention (WRAP). Logical Memory Test (LMT) and plasma p-tau217, p-tau181, p-tau231, Aβ42/Aβ40 ratio, GFAP and NfL levels were analyzed. Bayesian regression models assessed associations between plasma biomarkers and both process-based and traditional LMT scores, controlling for the covariates. Results: The best-fitting model for plasma p-tau217 included Total ratio (Tr) and Immediate recall (BF10=573), but Tr showed stronger evidence of association (mean coefficient = 0.208; BFinclusion=14.4) than Immediate recall (mean coefficient=-0.007; BFinclusion=1.7). Tr was also the best predictor of plasma p-tau181 (mean coefficient = 0.144; BF10=10.5) and GFAP (mean coefficient = 0.141; BF10=5.8), outperforming traditional LMT scores. No memory scores were associated with plasma p-tau231 or Aβ42/40 ratio levels. Tr score was the strongest single predictor of p-tau217 positivity (BF10=38). Conclusions: These findings suggest that process-based memory scores might be useful in enhancing the detection of neuronal network disturbances associated with AD pathology, especially in settings where biomarker testing is unavailable.

逻辑记忆测试故事回忆指标与无痴呆个体阿尔茨海默病血浆生物标志物之间的关联
目的:基于血液的生物标志物因其较低的成本和较少的侵入性而受到重视,尽管广泛实施和可及性的问题仍然存在。基于过程的故事回忆分数已经被证明比传统的指标更有效地检测阿尔茨海默病(AD)病理的典型神经网络紊乱。本研究在无痴呆的老年人中检查了基于过程的评分和并发血浆AD生物标志物之间的关系,同时也将其与传统指标进行了比较。此外,它还研究了这些指标在检测血浆p-tau217阳性中的诊断效用。方法:从威斯康星州阿尔茨海默病预防登记处(WRAP)提取416名无痴呆患者(平均年龄= 66.6±7)的数据。分析逻辑记忆测试(LMT)和血浆p-tau217、p-tau181、p-tau231、a - β42/ a - β40比值、GFAP和NfL水平。贝叶斯回归模型评估了血浆生物标志物与基于过程的和传统的LMT评分之间的关联,控制了协变量。结果:血浆p-tau217的最佳拟合模型包括总比(Tr)和立即召回率(BF10=573),但Tr的相关性更强(平均系数= 0.208;结论=14.4)优于立即召回(平均系数=-0.007;BFinclusion = 1.7)。Tr也是血浆p-tau181的最佳预测因子(平均系数= 0.144;BF10=10.5)和GFAP(平均系数= 0.141;BF10=5.8),优于传统的LMT分数。记忆评分与血浆p-tau231或a - β42/40比值水平无关。Tr评分是p-tau217阳性的最强单一预测因子(BF10=38)。结论:这些发现表明,基于过程的记忆评分可能有助于增强对与阿尔茨海默病病理相关的神经网络紊乱的检测,特别是在无法进行生物标志物检测的情况下。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Neuropsychologist
Clinical Neuropsychologist 医学-临床神经学
CiteScore
8.40
自引率
12.80%
发文量
61
审稿时长
6-12 weeks
期刊介绍: The Clinical Neuropsychologist (TCN) serves as the premier forum for (1) state-of-the-art clinically-relevant scientific research, (2) in-depth professional discussions of matters germane to evidence-based practice, and (3) clinical case studies in neuropsychology. Of particular interest are papers that can make definitive statements about a given topic (thereby having implications for the standards of clinical practice) and those with the potential to expand today’s clinical frontiers. Research on all age groups, and on both clinical and normal populations, is considered.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信